Overall survival: is it an objective endpoint for assessing the quality of surgical treatment for colorectal cancer?
Authors:
L. Martínek 1; P. Zonča 2; P. Ihnát 1
Authors‘ workplace:
Chirurgická klinika FN Ostrava, přednosta: doc. MUDr. P. Zonča, Ph. D., FRCS
1; Katedra chirurgických oborů LF OU v Ostravě, vedoucí katedry: Doc. MUDr. P. Zonča, Ph. D., FRCS
2
Published in:
Rozhl. Chir., 2013, roč. 92, č. 12, s. 690-693.
Category:
Review
Overview
The monitoring of the quality of surgical treatment is the basic condition for improving the results of medical care. There are various endpoints available to assess the quality of surgical care. Survival time traditionally represents the key parameter for patients with colorectal cancer. Overall survival should not, however, be the only standard accepted measure of surgical care quality. Disease free survival in the early stages, neoadjuvant or adjuvant settings has been validated as a better option. Progression free survival, alone or aggregated with the quality of life, provides a useful, more sensitive parameter for advanced or metastatic colorectal cancer.
The selection of appropriate, valid end-points is the basic prerequisite for improving the quality of surgical care for patients with colorectal cancer.
Key words:
colorectal cancer – disease free survival – progression free survival – overall survival
Sources
1. Guňková P, Guňka I, Martínek L, et al. Vliv dehiscence anastomózy na onkologické výsledky u resekčních výkonů pro karcinomu rekta. Rozhl Chir 2013;92:244–249.
2. FDA (U.S. Food and Drug Administration). Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. [on line] May 2007 [cit. 2013-07-21]. Dostupný na http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071590.pdf.
3. Matsuyama R, Reddy S, Smith TJ. Why do patiens choose chemotherapy near to end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006;24:3490–3496.
4. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 1990;300:1458–1460.
5. Balmer CE, Thomas P, Osborne RJ. Who wants second-line paliative chemotherapy? Psychooncology 2001;10:410–418.
6. Crawford ED, Bennet CL, Stone NN, et al. Comparison of perspectives on prostate cancer. Analyses of survey data. Urology 1997;50:366–372.
7. McCain JA. The ongoing evolution of endpoints in oncology. Supplement to Managed care 2010;19:1–11.
8. Bergisson H, Walin U, Holberg L, et al. Survival endopints in colorectal cancer and the effect of second primary other cancer on disease free survival. BMC Cancer 2011;11:438–449.
9. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival then evaluating oncologic products. J Clin Oncol 2009;27:2874–2880.
10. Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7–12.
11. Chirila C, Odom D, Devercelli G, et al. Meta-analysis of the association between progression-free survival and overall survival in metastattic colorectal cancer. Int J Colorectal Dis 2012;27: 623–634.
12. Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate end-points in cancer clinical trials. Int J Clin Oncol 2009;14: 102–111.
13. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual pacient data from 20 898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol 2007;25: 4569–4574.
14. Methy N, Bedenne L, Conroy T, et al. Surrogate endpoints in neoadjuvant rectal cancer trials: Statistic evaluation using data from the FFCD 9203 trial. Ann Oncol 2009;21:518–524.
15. Tang PA, Bentzen SM, Chen EX, et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25:4562–4568.
16. ZHuang SH, Xiu L, Elsazed YA. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end point of drug efficacy. Cancer J 2009;15:395–400.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2013 Issue 12
Most read in this issue
- Positive sentinel node in breast cancer – when and why also opt for axillary dissection?
- Epithelial cyst in an intrapancreatic accessory spleen – a case report
- Minimally invasive video-assisted parathyroidectomy (MIVAP) using primary hyperparathyroidism therapy (pHPT)
- Is accurate preoperative assessment of pancreatic cystic lesions possible?